TY - JOUR

T1 - Стеатогепатиты смешанного генеза:

T2 - больше вопросов, чем ответов (Часть 1)

AU - Raikhelson, K. L.

AU - Kondrashina, E. A.

AU - Pazenko, E. V.

N1 - Райхельсон, К.Л. Стеатогепатиты смешанного генеза: больше вопросов, чем ответов (часть 1). / К. Л. Райхельсон, Э. А. Кондрашина, Е. В. Пазенко // Терапевтический архив. — Т. 92 (12). — с. 91-96.

PY - 2020/12/15

Y1 - 2020/12/15

N2 - The term "steatohepatitis" is used for a heterogeneous group of diseases of various etiologies, characterized by a similar morphological picture. Earlier the diagnosis of non-alcoholic fatty liver disease implied the exclusion of other causes of steatohepatitis, in recent years it has been suggested that a combination of various etiological variants of steatohepatitis is possible. The review considers the terminological, epidemiological and pathogenetic aspects of the most common combination: metabolic and alcoholic genesis, the issues of the mutual influence of etiopathogenetic factors and the identification of the predominant process. Issues of existing and prospective pathogenetic and symptomatic therapy are discussed in detail. Treatment of steatohepatitis is based on the elimination of known causal factors and lifestyle modification; therapy includes medications, that have been proven to be effective in certain types of steatohepatitis and symptomatic therapy as well.

AB - The term "steatohepatitis" is used for a heterogeneous group of diseases of various etiologies, characterized by a similar morphological picture. Earlier the diagnosis of non-alcoholic fatty liver disease implied the exclusion of other causes of steatohepatitis, in recent years it has been suggested that a combination of various etiological variants of steatohepatitis is possible. The review considers the terminological, epidemiological and pathogenetic aspects of the most common combination: metabolic and alcoholic genesis, the issues of the mutual influence of etiopathogenetic factors and the identification of the predominant process. Issues of existing and prospective pathogenetic and symptomatic therapy are discussed in detail. Treatment of steatohepatitis is based on the elimination of known causal factors and lifestyle modification; therapy includes medications, that have been proven to be effective in certain types of steatohepatitis and symptomatic therapy as well.

KW - стеатогепатит, неалкогольная жировая болезнь печени, алкогольная болезнь печени, адеметионин

KW - DECREASED PREVALENCE

KW - DISEASE

KW - FIBROSIS

KW - HEPATIC STEATOSIS

KW - HEPATOCELLULAR-CARCINOMA

KW - MODEST ALCOHOL-CONSUMPTION

KW - NONALCOHOLIC FATTY LIVER

KW - RISK-FACTORS

KW - S-ADENOSYLMETHIONINE

KW - VITAMIN-E

KW - ademetionine

KW - alcoholic liver disease

KW - drug-induced liver injury

KW - non-alcoholic fatty liver disease

KW - steatohepatitis

KW - Ademetionine

KW - Alcoholic liver disease

KW - Steatohepatitis

KW - Drug-induced liver injury

KW - Non-alcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=85100647341&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/a309ee85-29d4-35ec-bd62-39dbe380cb82/

U2 - 10.26442/00403660.2020.12.200470

DO - 10.26442/00403660.2020.12.200470

M3 - статья

AN - SCOPUS:85100647341

VL - 92

SP - 91

EP - 96

JO - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)

JF - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)

SN - 0040-3660

IS - 12

ER -